Management of Suppressed TSH (<0.1 mIU/L) in Lactating Women with Severe Osteoporosis

Diagnostic Confirmation

• Repeat the TSH measurement 2–4 weeks after the initial result, together with free T4 and total or free T3, to verify subclinical hyperthyroidism. 1

Etiology Assessment

• Investigate the cause of the suppressed TSH (e.g., Graves disease, toxic nodules, thyroiditis) by measuring TSH‑receptor antibodies and, when nodules are present, performing thyroid scintigraphy. 1

Cardiovascular Evaluation

• Screen for cardiac complications such as arrhythmias and atrial fibrillation, which are especially relevant in patients with subclinical hyperthyroidism. 1

Bone‑Related Risks

• In post‑menopausal women, a TSH < 0.1 mIU/L is linked to a markedly accelerated loss of bone mineral density (BMD). 1
• A TSH level of 0.1 mIU/L represents the threshold at which the risk of fractures becomes statistically significant, justifying treatment at this point. 1
• Restoring TSH to the normal range stabilizes BMD and prevents further bone loss. 1

Therapeutic Guidance for Overtreated Levothyroxine

• Reduce levothyroxine dosage until the TSH rises above 0.4 mIU/L to avoid the adverse skeletal effects of suppressed TSH. 2

Post‑partum Hormone Management

• After delivery, the maternal requirement for thyroid hormone typically declines, necessitating a dose adjustment of replacement therapy. 2
• Re‑measure TSH every 4–6 weeks postpartum until it remains within the normal reference interval (0.4–4.0 mIU/L). [2][1]